Cetera Investment Advisers Increases Stock Holdings in IQVIA Holdings Inc. $IQV

Cetera Investment Advisers raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 37.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 100,093 shares of the medical research company’s stock after buying an additional 27,412 shares during the quarter. Cetera Investment Advisers’ holdings in IQVIA were worth $15,774,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of IQV. Everpar Advisors LLC raised its position in shares of IQVIA by 4.6% in the 2nd quarter. Everpar Advisors LLC now owns 1,404 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 62 shares during the last quarter. Private Trust Co. NA increased its stake in IQVIA by 12.5% during the 2nd quarter. Private Trust Co. NA now owns 603 shares of the medical research company’s stock valued at $95,000 after purchasing an additional 67 shares in the last quarter. Independent Advisor Alliance raised its holdings in shares of IQVIA by 4.2% in the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock worth $318,000 after buying an additional 72 shares during the last quarter. Nemes Rush Group LLC lifted its stake in shares of IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock worth $109,000 after buying an additional 81 shares during the period. Finally, Penserra Capital Management LLC grew its holdings in shares of IQVIA by 10.3% during the second quarter. Penserra Capital Management LLC now owns 963 shares of the medical research company’s stock valued at $151,000 after buying an additional 90 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on IQV. Citigroup raised their target price on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 29th. Redburn Partners set a $214.00 price objective on IQVIA in a research note on Wednesday, September 3rd. Truist Financial reiterated a “buy” rating and issued a $265.00 target price (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, Barclays lifted their price objective on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $240.61.

IQVIA Trading Up 0.1%

IQVIA stock opened at $217.50 on Thursday. The firm has a market cap of $37.04 billion, a PE ratio of 29.84, a P/E/G ratio of 2.44 and a beta of 1.34. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $228.12. The stock’s 50 day simple moving average is $204.51 and its two-hundred day simple moving average is $180.05. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same period in the previous year, the business posted $2.84 EPS. The business’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.